FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129964076> ?p ?o ?g. }

• W2129964076 endingPage "267" @default.
• W2129964076 startingPage "259" @default.
• W2129964076 abstract "Corticosteroids are considered to be particularly effective in reducing nasal congestion and are therefore recommended as first-line treatment in allergic rhinitis patients with moderate to severe and/or persistent symptoms.We compared the clinical efficacy of fluticasone propionate aqueous nasal spray (FPANS) 200 microg given once daily, administered in mono-therapy or combined therapy with a H1 receptor antagonist (cetirizine, CTZ) or with a leukotriene antagonist (montelukast, MSK), and the combined therapy of CTZ plus MSK in the treatment of patients affected by allergic rhinitis to Parietaria during natural pollen exposure. In addition, we examined the effect of the treatment on eosinophil counts and eosinophil cationic protein (ECP) in nasal lavage performed at beginning of season, during season and at the end of the season.One hundred patients aged 12-50 years (mean+/-SD 31.8+/-9.6) with a history of moderate to severe Parietaria pollen-induced seasonal allergic rhinitis were selected. A randomized, double-blind, double dummy, placebo (PLA)-controlled, parallel-group study design was used. Patients were treated FPANS 200 microg once daily (n=20) or with FPANS 200 microg once daily, plus CTZ (10 mg) in the morning (n=20), or with FPANS 200 microg once daily, plus MSK (10 mg) in the evening (n=20) or with CTZ (10 mg) in the morning plus MSK in the evening (n=20) or matched PLA (n=20). Assessment of efficacy was based on scores of daily nasal symptoms and on eosinophil counts and ECP in nasal lavage.All treatments showed significant differences (P<0.001) compared with PLA in terms of total symptom, rhinorrhea, sneezing and nasal itching scores. Concerning nasal congestion on waking and daily only the groups treated with FPANS in mono-therapy or in combined therapy showed significant differences compared with PLA. Comparing the group treated with FPANS alone and the groups treated with FPANS plus CTZ, we found significant differences for total symptom score (P=0.04) and for nasal itching (P=0.003). The comparison between FPANS plus CTZ and FPANS plus MSK showed significant difference for nasal itching (P=0.003). Finally, there were significant differences between the group treated with FPANS and the group treated with CTZ plus MSK for total symptom score (P=0.009), for nasal congestion on waking (P<0.001) and nasal congestion daily (P<0.001). Also the comparisons between the group treated with FPANS plus CTZ and the group treated with CTZ plus MSK demonstrated significant differences (P<0.001) for total symptom, for nasal congestion on waking and for nasal congestion on daily, for rhinorrhea (P=0.04) and for nasal itching (P=0.003) scores. Concerning the comparison between the group treated with FPANS plus MSK and the group treated with CTZ plus MSK we found significant differences for total symptom score (P=0.005), for nasal congestion on waking (P<0.001) and for nasal congestion on daily (P<0.001). No other differences were observed between the groups. Concerning blood eosinophil counts, significant differences were found between the treatments with FPANS in mono-therapy or in combined therapy with PLA group during and at the end of the season (P=0.0003 and P<0.0001, respectively). Concerning eosinophils and ECP in nasal lavage, all treatments showed significant differences (P<0.001) compared with PLA. Besides, there were significant differences (P<0.001) between the groups treated with FPANS alone or in combined therapy and the group treated with CTZ plus MSK.The results of this comparative study demonstrate that FPANS is highly effective for treating patients affected by allergic rhinitis, with efficacy exceeding that of CTZ plus MSK in combined therapy. In addition, the regular combined therapy of FPANS plus CTZ or plus MSK would not seem to offer substantial advantage with respect to FPANS in mono-therapy in patients affected by seasonal allergic rhinitis." @default.
• W2129964076 created "2016-06-24" @default.
• W2129964076 creator A5000443758 @default.
• W2129964076 creator A5008627190 @default.
• W2129964076 creator A5015945590 @default.
• W2129964076 creator A5024105736 @default.
• W2129964076 creator A5038797557 @default.
• W2129964076 creator A5039248291 @default.
• W2129964076 creator A5042392846 @default.
• W2129964076 creator A5054433356 @default.
• W2129964076 creator A5065645344 @default.
• W2129964076 creator A5067811540 @default.
• W2129964076 creator A5074863074 @default.
• W2129964076 creator A5088028044 @default.
• W2129964076 creator A5090837102 @default.
• W2129964076 date "2004-02-01" @default.
• W2129964076 modified "2023-10-15" @default.
• W2129964076 title "Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis" @default.
• W2129964076 cites W1966146541 @default.
• W2129964076 cites W1966159794 @default.
• W2129964076 cites W1978837864 @default.
• W2129964076 cites W1979420780 @default.
• W2129964076 cites W1981429149 @default.
• W2129964076 cites W1989772024 @default.
• W2129964076 cites W1997324711 @default.
• W2129964076 cites W2001316705 @default.
• W2129964076 cites W2001450061 @default.
• W2129964076 cites W2002817537 @default.
• W2129964076 cites W2016377904 @default.
• W2129964076 cites W2018771352 @default.
• W2129964076 cites W2026521974 @default.
• W2129964076 cites W2032470063 @default.
• W2129964076 cites W2042418540 @default.
• W2129964076 cites W2043603230 @default.
• W2129964076 cites W2063322970 @default.
• W2129964076 cites W2068797688 @default.
• W2129964076 cites W2093963620 @default.
• W2129964076 cites W2094983249 @default.
• W2129964076 cites W2096210343 @default.
• W2129964076 cites W2109306397 @default.
• W2129964076 cites W2117159720 @default.
• W2129964076 cites W2137043313 @default.
• W2129964076 cites W2155345300 @default.
• W2129964076 cites W4249911295 @default.
• W2129964076 doi "https://doi.org/10.1111/j.1365-2222.2004.01877.x" @default.
• W2129964076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14987306" @default.
• W2129964076 hasPublicationYear "2004" @default.
• W2129964076 type Work @default.
• W2129964076 sameAs 2129964076 @default.
• W2129964076 citedByCount "153" @default.
• W2129964076 countsByYear W21299640762012 @default.
• W2129964076 countsByYear W21299640762013 @default.
• W2129964076 countsByYear W21299640762014 @default.
• W2129964076 countsByYear W21299640762015 @default.
• W2129964076 countsByYear W21299640762016 @default.
• W2129964076 countsByYear W21299640762017 @default.
• W2129964076 countsByYear W21299640762018 @default.
• W2129964076 countsByYear W21299640762019 @default.
• W2129964076 countsByYear W21299640762020 @default.
• W2129964076 countsByYear W21299640762021 @default.
• W2129964076 countsByYear W21299640762022 @default.
• W2129964076 countsByYear W21299640762023 @default.
• W2129964076 crossrefType "journal-article" @default.
• W2129964076 hasAuthorship W2129964076A5000443758 @default.
• W2129964076 hasAuthorship W2129964076A5008627190 @default.
• W2129964076 hasAuthorship W2129964076A5015945590 @default.
• W2129964076 hasAuthorship W2129964076A5024105736 @default.
• W2129964076 hasAuthorship W2129964076A5038797557 @default.
• W2129964076 hasAuthorship W2129964076A5039248291 @default.
• W2129964076 hasAuthorship W2129964076A5042392846 @default.
• W2129964076 hasAuthorship W2129964076A5054433356 @default.
• W2129964076 hasAuthorship W2129964076A5065645344 @default.
• W2129964076 hasAuthorship W2129964076A5067811540 @default.
• W2129964076 hasAuthorship W2129964076A5074863074 @default.
• W2129964076 hasAuthorship W2129964076A5088028044 @default.
• W2129964076 hasAuthorship W2129964076A5090837102 @default.
• W2129964076 hasBestOaLocation W21299640762 @default.
• W2129964076 hasConcept C121332964 @default.
• W2129964076 hasConcept C126322002 @default.
• W2129964076 hasConcept C1276947 @default.
• W2129964076 hasConcept C142724271 @default.
• W2129964076 hasConcept C19720800 @default.
• W2129964076 hasConcept C204787440 @default.
• W2129964076 hasConcept C27081682 @default.
• W2129964076 hasConcept C2776042228 @default.
• W2129964076 hasConcept C2776322731 @default.
• W2129964076 hasConcept C2776476923 @default.
• W2129964076 hasConcept C2776804153 @default.
• W2129964076 hasConcept C2777037409 @default.
• W2129964076 hasConcept C2779028295 @default.
• W2129964076 hasConcept C2779463773 @default.
• W2129964076 hasConcept C2780212800 @default.
• W2129964076 hasConcept C2780973058 @default.
• W2129964076 hasConcept C2781212218 @default.
• W2129964076 hasConcept C42219234 @default.
• W2129964076 hasConcept C71924100 @default.
• W2129964076 hasConcept C85663871 @default.
• W2129964076 hasConcept C90924648 @default.

• next